Simplified Antihypertensive Therapy with Pindolol Retard

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1982 Jan 1

PMID 7075649

Citations 1

Authors

W Kiowski

K O Stumpe

F R Buhler

Affiliations

Soon will be listed here.

Abstract

36 out of 52 patients with essential hypertension, whose blood pressure was not normalized with pindolol 15 mg per day, were treated with 30 mg per day for four to six weeks. Pindolol was administered in random order, either as 15 mg twice daily or as one 30 mg retard tablet once daily. Blood pressure was lowered from mean pretreatment levels of 174/111 mmHg to 149/98 mmHg by 15 mg b.d., and to 145/97 mmHg by 30 mg retard. In five patients diurnal variations in blood pressure and plasma pindolol levels were determined. At all times during the day blood pressure was at least well controlled by 30 mg retard as by 15 mg b.d. Plasma concentration maxima were similar with both forms, but a higher concentration was maintained for a longer time after the retard tablet. Pindolol 30 mg was well tolerated and the incidence of side effects was lower than during treatment with 15 mg b.d. Thus, patients requiring high doses of pindolol for control of hypertension can safely and conveniently be treated with a single tablet of 30 mg pindolol retard.

Citing Articles

Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets.

Aellig W, Nuesch E, Pacha W Eur J Clin Pharmacol. 1982; 21(6):451-5.

PMID: 7075650 DOI: 10.1007/BF00542037.

References

Simon G, Kiowski W, Julius S . Antihypertensive and beta-adrenoceptor antagonist action of timolol. Clin Pharmacol Ther. 1978; 23(2):152-7. DOI: 10.1002/cpt1978232152. View

Cruickshank J . Once-daily dosing with Atenolol in patients with mild or moderate hypertension. Br Med J. 1976; 1(6016):990-1. PMC: 1639643. DOI: 10.1136/bmj.1.6016.990. View

Aellig W, Nuesch E, Pacha W . Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets. Eur J Clin Pharmacol. 1982; 21(6):451-5. DOI: 10.1007/BF00542037. View

Alhenc-Gelas F, Plouin P, Ducrocq M, Corvol P, Menard J . Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. Am J Med. 1978; 64(6):1005-12. DOI: 10.1016/0002-9343(78)90456-4. View

Frithz G, Danielson M, Henningsen N, MALMBORG R, NORDSTROM-OHRBERG G, Schroder G . Long-term blood pressure control with pindolol given once daily. Eur J Cardiol. 1978; 7(2-3):131-6. View

Prichard B, GILLAM P . Treatment of hypertension with propranolol. Br Med J. 1969; 1(5635):7-16. PMC: 1981816. DOI: 10.1136/bmj.1.5635.7. View

Buhler F, Burkart F, Lutold B, Kung M, Marbet G, Pfisterer M . Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975; 36(5):653-69. DOI: 10.1016/0002-9149(75)90168-x. View

Buhler F, Lutold B, Kung M, Koller F . Once daily dosage beta-blockade: antihypertensive efficacy of slow release oxprenolol as related to renin and age. Aust N Z J Med. 1976; 6(3 Suppl):37-43. DOI: 10.1111/j.1445-5994.1976.tb03333.x. View

SCHOENBERGER J, Stamler J, SHEKELLE R, Shekelle S . Current status of hypertension control in an industrial population. JAMA. 1972; 222(5):559-62. View

10.

Harris A, Wollard K, Tweed J . A study of once daily tenormin (atenolol) in hypertension: some implications in patient compliance. J Int Med Res. 1976; 4(5):347-51. DOI: 10.1177/030006057600400508. View

11.

Wilcox R . Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. Br Med J. 1978; 2(6134):383-5. PMC: 1609059. DOI: 10.1136/bmj.2.6134.383. View

12.

Morgan T, Louis W, DAWBORN J, Doyle A . The use of prindolol (Visken) in the treatment of hypertension. Med J Aust. 1972; 2(6):309-12. DOI: 10.5694/j.1326-5377.1972.tb47306.x. View

13.

Greenblatt D, Koch-Weser J . Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J. 1973; 86(4):478-84. DOI: 10.1016/0002-8703(73)90139-7. View

14.

STAMLER R, Stamler J, Civinelli J, Pritchard D, Gosch F, Ticho S . Adherence and blood-pressure response to hypertension treatment. Lancet. 1975; 2(7947):1227-30. DOI: 10.1016/s0140-6736(75)92070-x. View

15.

ZACHARIAS F, Cowen K, Prestt J, Vickers J, Wall B . Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J. 1972; 83(6):755-61. DOI: 10.1016/0002-8703(72)90206-2. View

16.

Simpson F . Beta-adrenergic receptor blocking drugs in hypertension. Drugs. 1974; 7(1):85-105. DOI: 10.2165/00003495-197407010-00006. View

17.

SEALEY J, LARAGH J . The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int. 1972; 1(4):240-53. DOI: 10.1038/ki.1972.34. View

18.

ZACHARIAS F . Patient acceptability of propranolol and the occurence of side effects. Postgrad Med J. 1976; 52 Suppl 4:87-9. View

19.

Clark G, TROOP R . One-tablet combination drug therapy in the treatment of hypertension. J Chronic Dis. 1972; 25(2):57-64. DOI: 10.1016/0021-9681(72)90141-5. View

20.

Wilson M, MORGAN G, Morgan T . The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased. Br J Clin Pharmacol. 1976; 3(5):857-61. PMC: 1428952. DOI: 10.1111/j.1365-2125.1976.tb00638.x. View